| Fees in Shares and Total Voting Rights Released: 04/08/2010
04 August 2010, London, UK, and Cambridge, MA: Cancer drug developer Antisoma
plc (LSE: ASM; USOTC: ATSMY) today announces that three Non-Executive Directors
of Antisoma have taken all or part of their fees for the month ended 31 July
2010 in ordinary shares pursuant to resolutions of the Board of Directors dated
14 September 2004 and subsequently.
The new ordinary shares were issued at a price of 5.3 pence per share, this
being the mid-market closing price on the last trading day of the month (30 July
2010). The relevant Directors have agreed not to dispose of the shares allotted
for a minimum period of one year.
The allotment and total holdings following this allotment are shown below.
+-----------------------+---------+-------------+-
|Director |Allotted |Total holding|Percentage of issued ordinary |
| |02 Aug 10| |shares |
| | | | |
+-----------------------+---------+-------------+-
|Barry Price |35,377 |1,018,173 |0.16% |
+-----------------------+---------+-------------+-
|Birgit Stattin-Norinder|14,544 |90,124 |0.01% |
+-----------------------+---------+-------------+-
|Michael Lewis |55,031 |503,012 |0.08% |
+-----------------------+---------+-------------+-
Application will be made to the London Stock Exchange and the UK Listing
Authority for the admission of the new ordinary shares of 1p each. The total
number of ordinary shares in the Company in issue and admitted to the Official
List following the above allotments will be 630,073,950.
The new ordinary shares will rank pari passu with the Company's existing
ordinary shares.
Enquiries:
Alison Saville, Senior Marketing and Communications Executive
Antisoma plc
+44 (0)20 3249 2100
Background on Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company that
develops novel products for the treatment of cancer. The Company has operations
in the UK and the US. Please visit www.antisoma.com for further information
about Antisoma.
[HUG#1435843]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
|
